サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1531904

化学療法誘発性骨髄抑制治療の世界市場レポート 2024年

Chemotherapy-Induced Myelosuppression Treatment Global Market Report 2024

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.95円
化学療法誘発性骨髄抑制治療の世界市場レポート 2024年
出版日: 2024年08月12日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

化学療法誘発性骨髄抑制治療の市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR4.7％で96億米ドルに成長します。予測期間中に予想される成長は、がん患者数の増加、患者の意識向上、新治療法の採用拡大などに起因しています。予測期間に予想される主な動向には、費用対効果の高い治療の台頭、AIアルゴリズムソリューションの採用、大幅な技術進歩、新製品やサービスのイントロダクションなどが含まれます。

がんの有病率の増加は、今後の化学療法誘発性骨髄抑制治療市場の成長を促進すると予測されます。がんは、しばしば周囲の組織や臓器に侵入し、その正常な機能を破壊し、個人の全体的な健康と幸福を脅かす可能性のある、異常な細胞の制御不能な増殖と拡散によって特徴付けられます。がんの罹患率の増加は、公害、放射線、特定の化学物質、発がん性物質への曝露に起因しています。化学療法誘発性骨髄抑制治療は、様々な種類のがんの標準治療である化学療法によって引き起こされる血液学的副作用を管理するために、がん治療において極めて重要です。例えば、2024年5月、米国を拠点とする専門組織である米国臨床腫瘍学会は、2022年の新規がん患者数は推定2,000万人であり、2050年には全世界で3,500万人に達するとの予測を報告しています。このように、がんの有病率の増加が化学療法誘発性骨髄抑制治療市場に拍車をかけています。

化学療法誘発性骨髄抑制治療市場の開発企業は、骨髄保護療法などの革新的製品の開発に注力し、治療効果や患者体験を向上させています。骨髄保護療法には、化学療法や放射線療法などの治療によるダメージから骨髄や造血幹細胞を保護するための医療介入が含まれます。例えば、2021年2月、米国のバイオ医薬品会社であるG1セラピューティクス社は、成人患者における化学療法による骨髄抑制の頻度を減少させる注射用コセラ（トリラシクリブ）を発売しました。本剤は、米国連邦食品医薬品局（FDA）の承認を取得しました。この革新的なアプローチは、しばしば投与量の減少や治療の遅れにつながる好中球減少、貧血、血小板減少などの一般的な化学療法の副作用を軽減します。コセラは、様々ながん種における既存の化学療法レジメンにシームレスに統合され、患者の忍容性を高め、継続的な治療をサポートすることで、治療成績全体と生活の質を改善する可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の化学療法誘発性骨髄抑制治療市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の化学療法誘発性骨髄抑制治療市場の実績：規模と成長, 2018-2023
  • 世界の化学療法誘発性骨髄抑制治療市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界の化学療法誘発性骨髄抑制治療市場：適応症別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 貧血
  • 好中球減少症
  • 血小板減少症
  • 世界の化学療法誘発性骨髄抑制治療市場：薬剤クラス別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 成長因子
  • エリスロポエチン刺激剤
  • 血栓形成剤
  • 鉄サプリメント
  • その他の薬物クラス
  • 世界の化学療法誘発性骨髄抑制治療市場：投与経路別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 経口
  • 注射
  • 世界の化学療法誘発性骨髄抑制治療市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域別・国別分析

  • 世界の化学療法誘発性骨髄抑制治療市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界の化学療法誘発性骨髄抑制治療市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 化学療法誘発性骨髄抑制治療市場：競合情勢
  • 化学療法誘発性骨髄抑制治療市場：企業プロファイル
    • Pfizer Inc.
    • Merck & Co. Inc.
    • Bayer AG
    • Sanofi SA
    • Abbott Laboratories

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • Glaxo Smith Kline plc
  • Amgen Inc.
  • Viatris Inc.
  • Biogen SA
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Ltd
  • Seagen Inc
  • Mission Pharmacal Company
  • G1 Therapeutics Inc.
  • Spectrum Pharmaceuticals Inc.
  • Partner Therapeutics Inc.
  • Myelo Therapeutics GmbH

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r18815

Chemotherapy-induced myelosuppression treatment involves therapeutic interventions designed to manage and alleviate the suppression of bone marrow activity caused by chemotherapy drugs. The objective of treating chemotherapy-induced myelosuppression is to alleviate symptoms, prevent complications such as infections or bleeding disorders, and support patients in continuing their chemotherapy treatment.

The primary indications for chemotherapy-induced myelosuppression treatment are anemia, neutropenia, and thrombocytopenia. Anemia in this context refers to a condition where the body lacks sufficient healthy red blood cells, leading to fatigue, weakness, and shortness of breath. The various classes of drugs used include growth factors, erythropoietin-stimulating agents, thrombopoietic agents, iron supplements, and others. The market for chemotherapy-induced myelosuppression treatment includes oral and injectable routes of administration, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The chemotherapy-induced myelosuppression treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced myelosuppression treatment market statistics, including chemotherapy-induced myelosuppression treatment industry global market size, regional shares, competitors with a chemotherapy-induced myelosuppression treatment market share, detailed chemotherapy-induced myelosuppression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced myelosuppression treatment industry. This chemotherapy-induced myelosuppression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced myelosuppression treatment market size has grown steadily in recent years. It will grow from $7.65 billion in 2023 to $7.97 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historic period can be credited to the rising need for early diagnosis, the increasing incidence of leukemia, and the heightened focus on research and development.

The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $9.60 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%. The anticipated growth during the forecast period can be attributed to the rising number of cancer patients, increased patient awareness, and the growing adoption of new therapies. Key trends expected in the forecast period include the rise of cost-effective treatments, the adoption of AI algorithm solutions, significant technological advancements, and the introduction of new products and services.

The increasing prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced myelosuppression treatment market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which often invade surrounding tissues and organs, disrupting their normal functions and potentially threatening the individual's overall health and well-being. The rising incidence of cancer can be attributed to exposure to pollution, radiation, certain chemicals, and carcinogens. Chemotherapy-induced myelosuppression treatment is crucial in cancer care for managing the hematological side effects caused by chemotherapy, a standard treatment for various cancer types. For example, in May 2024, the American Society of Clinical Oncology, a US-based professional organization, reported an estimated 20 million new cancer cases in 2022, with projections reaching 35 million new cases globally by 2050. Thus, the increasing prevalence of cancer is fueling the chemotherapy-induced myelosuppression treatment market.

Leading companies in the chemotherapy-induced myelosuppression treatment market focus on developing innovative products, such as myeloprotection therapy, to improve treatment efficacy and patient experience. Myeloprotection therapy involves medical interventions designed to protect the bone marrow and hematopoietic stem cells from damage caused by treatments such as chemotherapy and radiation therapy. For instance, in February 2021, G1 Therapeutics Inc., a US-based biopharmaceutical company, launched COSELA (trilaciclib) for injection to reduce the frequency of myelosuppression caused by chemotherapy in adult patients. This product was approved by the Food and Drug Administration (FDA), a US-based federal agency. This innovative approach alleviates common chemotherapy side effects such as neutropenia, anemia, and thrombocytopenia, which often lead to dose reductions or treatment delays. Cosela integrates seamlessly into existing chemotherapy regimens across different cancer types, enhancing patient tolerance and supporting continuous therapy delivery, potentially improving overall treatment outcomes and quality of life.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to expand its portfolio in oncology and biopharmaceuticals by leveraging Seagen's expertise in antibody-drug conjugates and targeted cancer therapies. This move is intended to strengthen Pfizer's position in the oncology market and advance patient treatment options. Seagen Inc. is a US-based company that develops innovative monoclonal antibody-based therapies for chemotherapy-induced myelosuppression.

Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.

North America was the largest region in the chemotherapy-induced myelosuppression treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced myelosuppression treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemotherapy-induced myelosuppression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced myelosuppression treatment market includes revenues earned by entities by providing services such as red blood cell transfusions, platelet transfusions, antibiotic therapy, and supportive care and related erythropoiesis-stimulating agents, antibiotics, colony-stimulating factors (CSFs), diagnostic kits and hydration solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Myelosuppression Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced myelosuppression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced myelosuppression treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced myelosuppression treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Indication: Anemia; Neutropenia; Thrombocytopenia
  • 2) By Drug Class: Growth Factors; Erythropoietin Stimulating Agents; Thrombopoietic Agents; Iron Supplements; Other Drug Classes
  • 3) By Route Of Administration: Oral; Injectable
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Myelosuppression Treatment Market Characteristics

3. Chemotherapy-Induced Myelosuppression Treatment Market Trends And Strategies

4. Chemotherapy-Induced Myelosuppression Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chemotherapy-Induced Myelosuppression Treatment Market Size and Growth

  • 5.1. Global Chemotherapy-Induced Myelosuppression Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chemotherapy-Induced Myelosuppression Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chemotherapy-Induced Myelosuppression Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chemotherapy-Induced Myelosuppression Treatment Market Segmentation

  • 6.1. Global Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anemia
  • Neutropenia
  • Thrombocytopenia
  • 6.2. Global Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Growth Factors
  • Erythropoietin Stimulating Agents
  • Thrombopoietic Agents
  • Iron Supplements
  • Other Drug Classes
  • 6.3. Global Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • 6.4. Global Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Chemotherapy-Induced Myelosuppression Treatment Market Regional And Country Analysis

  • 7.1. Global Chemotherapy-Induced Myelosuppression Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chemotherapy-Induced Myelosuppression Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market

  • 8.1. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chemotherapy-Induced Myelosuppression Treatment Market

  • 9.1. China Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 9.2. China Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chemotherapy-Induced Myelosuppression Treatment Market

  • 10.1. India Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chemotherapy-Induced Myelosuppression Treatment Market

  • 11.1. Japan Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 11.2. Japan Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chemotherapy-Induced Myelosuppression Treatment Market

  • 12.1. Australia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chemotherapy-Induced Myelosuppression Treatment Market

  • 13.1. Indonesia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chemotherapy-Induced Myelosuppression Treatment Market

  • 14.1. South Korea Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 14.2. South Korea Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market

  • 15.1. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 15.2. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chemotherapy-Induced Myelosuppression Treatment Market

  • 16.1. UK Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chemotherapy-Induced Myelosuppression Treatment Market

  • 17.1. Germany Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chemotherapy-Induced Myelosuppression Treatment Market

  • 18.1. France Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chemotherapy-Induced Myelosuppression Treatment Market

  • 19.1. Italy Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chemotherapy-Induced Myelosuppression Treatment Market

  • 20.1. Spain Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market

  • 21.1. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 21.2. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chemotherapy-Induced Myelosuppression Treatment Market

  • 22.1. Russia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chemotherapy-Induced Myelosuppression Treatment Market

  • 23.1. North America Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 23.2. North America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chemotherapy-Induced Myelosuppression Treatment Market

  • 24.1. USA Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 24.2. USA Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chemotherapy-Induced Myelosuppression Treatment Market

  • 25.1. Canada Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 25.2. Canada Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chemotherapy-Induced Myelosuppression Treatment Market

  • 26.1. South America Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 26.2. South America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chemotherapy-Induced Myelosuppression Treatment Market

  • 27.1. Brazil Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chemotherapy-Induced Myelosuppression Treatment Market

  • 28.1. Middle East Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 28.2. Middle East Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chemotherapy-Induced Myelosuppression Treatment Market

  • 29.1. Africa Chemotherapy-Induced Myelosuppression Treatment Market Overview
  • 29.2. Africa Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chemotherapy-Induced Myelosuppression Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chemotherapy-Induced Myelosuppression Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Chemotherapy-Induced Myelosuppression Treatment Market Competitive Landscape
  • 30.2. Chemotherapy-Induced Myelosuppression Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi SA
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Abbott Laboratories
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chemotherapy-Induced Myelosuppression Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Glaxo Smith Kline plc
  • 31.3. Amgen Inc.
  • 31.4. Viatris Inc.
  • 31.5. Biogen SA
  • 31.6. Bausch Health Companies Inc.
  • 31.7. Cipla Inc.
  • 31.8. Hikma Pharmaceuticals PLC
  • 31.9. Lupin Ltd
  • 31.10. Seagen Inc
  • 31.11. Mission Pharmacal Company
  • 31.12. G1 Therapeutics Inc.
  • 31.13. Spectrum Pharmaceuticals Inc.
  • 31.14. Partner Therapeutics Inc.
  • 31.15. Myelo Therapeutics GmbH

32. Global Chemotherapy-Induced Myelosuppression Treatment Market Competitive Benchmarking

33. Global Chemotherapy-Induced Myelosuppression Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chemotherapy-Induced Myelosuppression Treatment Market

35. Chemotherapy-Induced Myelosuppression Treatment Market Future Outlook and Potential Analysis

  • 35.1 Chemotherapy-Induced Myelosuppression Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chemotherapy-Induced Myelosuppression Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chemotherapy-Induced Myelosuppression Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer